Overview

Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Tamoxifen may fight breast cancer by blocking the use of estrogen. Combining tipifarnib with tamoxifen may be effective treatment for metastatic breast cancer. PURPOSE: This phase II trial is studying how well giving tipifarnib together with tamoxifen works in treating women with metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Tamoxifen
Tipifarnib